AMRX Quote, Financials, Valuation and Earnings

Invivyd has a net margin of -4.26% compared to Amneal Pharmaceuticals's net margin of -653.11%. Amneal Pharmaceuticals's return on equity of -587.3% beat Invivyd's return on equity of --.

Amneal Pharmaceuticals has a consensus price target of $11.50, signalling upside risk potential of 33.41%. On the other hand Invivyd has an analysts' consensus of $6.67 which suggests that it could grow by 728.47%. Given that Invivyd has higher upside potential than Amneal Pharmaceuticals, analysts believe Invivyd is more attractive than Amneal Pharmaceuticals.

Amneal Pharmaceuticals has a beta of 1.049, which suggesting that the stock is 4.898% more volatile than S&P 500. In comparison Invivyd has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invivyd offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. Invivyd pays out -- of its earnings as a dividend.

Amneal Pharmaceuticals quarterly revenues are $730.5M, which are larger than Invivyd quarterly revenues of $9.3M. Amneal Pharmaceuticals's net income of -$31.1M is higher than Invivyd's net income of -$60.7M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is 101.17x while Invivyd's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.96x versus -- for Invivyd. Usually stocks with elevated PS ratios are considered overvalued.

PepGen has a net margin of -4.26% compared to Amneal Pharmaceuticals's net margin of --. Amneal Pharmaceuticals's return on equity of -587.3% beat PepGen's return on equity of --.

Amneal Pharmaceuticals has a consensus price target of $11.50, signalling upside risk potential of 33.41%. On the other hand PepGen has an analysts' consensus of $12.20 which suggests that it could grow by 409.4%. Given that PepGen has higher upside potential than Amneal Pharmaceuticals, analysts believe PepGen is more attractive than Amneal Pharmaceuticals.

Amneal Pharmaceuticals has a beta of 1.049, which suggesting that the stock is 4.898% more volatile than S&P 500. In comparison PepGen has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PepGen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. PepGen pays out -- of its earnings as a dividend.

Amneal Pharmaceuticals quarterly revenues are $730.5M, which are larger than PepGen quarterly revenues of --. Amneal Pharmaceuticals's net income of -$31.1M is lower than PepGen's net income of -$22.2M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is 101.17x while PepGen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.96x versus -- for PepGen. Usually stocks with elevated PS ratios are considered overvalued.

Staar Surgical has a net margin of -4.26% compared to Amneal Pharmaceuticals's net margin of -69.92%. Amneal Pharmaceuticals's return on equity of -587.3% beat Staar Surgical's return on equity of -5.02%.

Amneal Pharmaceuticals has a consensus price target of $11.50, signalling upside risk potential of 33.41%. On the other hand Staar Surgical has an analysts' consensus of $18.67 which suggests that it could grow by 9.35%. Given that Amneal Pharmaceuticals has higher upside potential than Staar Surgical, analysts believe Amneal Pharmaceuticals is more attractive than Staar Surgical.

Amneal Pharmaceuticals has a beta of 1.049, which suggesting that the stock is 4.898% more volatile than S&P 500. In comparison Staar Surgical has a beta of 0.660, suggesting its less volatile than the S&P 500 by 34.006%.

Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Staar Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. Staar Surgical pays out -- of its earnings as a dividend.

Amneal Pharmaceuticals quarterly revenues are $730.5M, which are larger than Staar Surgical quarterly revenues of $49M. Amneal Pharmaceuticals's net income of -$31.1M is higher than Staar Surgical's net income of -$34.2M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is 101.17x while Staar Surgical's PE ratio is 49.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.96x versus 2.69x for Staar Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of -4.26% compared to Amneal Pharmaceuticals's net margin of 8.8%. Amneal Pharmaceuticals's return on equity of -587.3% beat Supernus Pharmaceuticals's return on equity of 7.61%.

Amneal Pharmaceuticals has a consensus price target of $11.50, signalling upside risk potential of 33.41%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $38.80 which suggests that it could grow by 24.12%. Given that Amneal Pharmaceuticals has higher upside potential than Supernus Pharmaceuticals, analysts believe Amneal Pharmaceuticals is more attractive than Supernus Pharmaceuticals.

Amneal Pharmaceuticals has a beta of 1.049, which suggesting that the stock is 4.898% more volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.835, suggesting its less volatile than the S&P 500 by 16.47%.

Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend.

Amneal Pharmaceuticals quarterly revenues are $730.5M, which are larger than Supernus Pharmaceuticals quarterly revenues of $174.2M. Amneal Pharmaceuticals's net income of -$31.1M is lower than Supernus Pharmaceuticals's net income of $15.3M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is 101.17x while Supernus Pharmaceuticals's PE ratio is 23.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.96x versus 2.64x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.